The pharmaceutical sector is becoming complex due to rising R&D costs, regulatory barriers, and payer expectations, and it has become difficult for pharma companies to successfully launch their drugs/ therapies in the market. Thus, having an appropriate market access strategy during this process is a clear competitive advantage for companies.
Key Market Access-related Challenges Pharma Companies Encounter
Although drug development and commercialization trends are increasingly favorable, there are several hurdles that delay access to novel therapies either directly or indirectly. Some of these issues are caused by external factors, while others are the result of internal inefficiencies within the commercialization process.
- Regulatory Delays: While regulatory agencies try to streamline the approval process, variations in the documentation and criteria can significantly reduce the speed to market. For example, J&J’s subcutaneous formulation of Rybrevant failed the FDA approval test for EGFR-mutated non-small cell lung cancer.
- Pricing and Reimbursement Issues: Innovative therapies often face payer pushback on price levels that are considered too high compared to their value. At the same time, political and legislative developments can significantly impact pricing and reimbursement of the drugs or therapies. An appropriate example is the US Inflation Reduction Act, which has introduced new drug-price negotiation mechanisms that can influence the pricing of certain medicines.
- Market Competition: The competitive landscape: An influx of biosimilars and generic drugs into the market creates a challenge for biological companies to justify the high cost of their treatment in terms of the quality of care and patient compliance.
Recommended Strategies to Overcome These Challenges
To overcome market access hurdles more effectively, pharma companies need to follow a more multi-faceted and forward-looking approach. One of the most effective ways to de-risk the launch of a drug in the market is engaging the relevant stakeholders at the outset of the drug development process. This allows pharma to speed up the approval process at regulatory, payer, and provider levels with more confidence. Similarly, integrating real-world evidence into the drug development process holds great promise in elevating the drug’s innovative potential and its market accessibility in the eyes of healthcare providers, professionals, as well as payers.
Health Economics and Outcomes Research (HEOR) provides an opportunity to quantify treatment’s economic and quality-of-life benefits, which serves as a solid foundation for reimbursement outcomes-related discussions. Additionally, introducing an innovative approach to pricing, such as value-based pricing or outcome-based agreements, enables introducing flexible, outcome-driven solutions that are especially relevant in emerging and resource-constrained markets.
These strategies allow pharma companies to not only ensure the success of their innovative therapies but also sustain their businesses within pharma’s ever-evolving market access space.
Unlock how we helped a pharmaceutical company surpass its original sales forecast by 30% with our tailored strategic market penetration plan and robust stakeholder engagement.
Fill out the form to access the complete case study.
